Komori
Immuno-Biological Laboratories (4570) · PolicyRaisedLatest Earnings (2026-08-07): "Restated"

Consistent, Stable Dividends and Reinvestment in Research and Development

First written in FY2016. 6 of 12 entries say "Raised", first in FY2025. Latest entry: 2026-08-07.

12entries
11years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20242016: 120162017: 120172018: 020182019: 120192020: 020202021: 020212022: 020222023: 020232024: 120242025: 120252026: 72026
Same theme, other companies
Capital allocation policy balancing future investment and shareholder dividendsA theme 469 companies write about · 0 as a headwind · 471 as a tailwind

80 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 473 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-07RestatedEarnings

    「Fiscal year ending March 2027 (forecast) 0.00 — 7.50 7.50」

    The forecast for a full-year dividend of ¥7.5 for the fiscal year ending March 2027 was reconfirmed without revision from the most recently published forecast.
  2. FY2026RaisedAnnual report

    「The Company set the dividend from surplus for the current fiscal year at ¥6 per share. For the next fiscal year, it plans to pay an annual dividend of ¥7.5 per share, representing a consolidated payout ratio of approximately 20.1%. Going forward, it will continue seeking to increase dividend returns to shareholders while enhancing corporate value.」

    The Company paid an annual dividend of ¥6 per share, raised its planned dividend for the next fiscal year from ¥6 to ¥7.5 per share and indicated a consolidated payout ratio of approximately 20.1%.
  3. FY2025RaisedAnnual report

    「For the next fiscal year, the Company plans to pay an annual dividend of ¥6 per share, representing a consolidated payout ratio of approximately 21.1%. Going forward, it will continue seeking to increase dividend returns to shareholders while enhancing corporate value.」

    Although the Company continued to pay no dividend for the current fiscal year, it presented a specific dividend plan for the next fiscal year for the first time: an annual dividend of ¥6 per share and a consolidated payout ratio of approximately 21.1%.
  4. FY2024RestatedAnnual report

    「Based on this policy, the Company paid no dividend from surplus for the fiscal year despite achieving a return to net profitability, taking into account the level of retained earnings.」

    Although the Company returned to net profitability, it paid no dividend because of the level of retained earnings and continues its basic policy of balancing dividends with retained earnings.
  5. FY2019RestatedAnnual report

    「Based on this policy, the Company paid no dividend from surplus for the fiscal year, taking into account its inability to record a profit and the level of retained earnings. It plans to reinvest retained earnings in R&D to enhance corporate value and improve return on equity.」

    While maintaining a basic policy of sustainable, stable dividends, the Company paid no dividend for the fiscal year because it was unable to record a profit, among other reasons, and indicated a policy of reinvesting retained earnings in R&D.
  6. FY2017RestatedAnnual report

    「The Company recognizes the return of profits to shareholders as one of management's key priorities. Its basic policy is to maintain a strong management base, secure stable earnings, improve return on equity and pay sustainable, stable dividends.」

    The Company reaffirmed its basic policy of balancing dividends with retained earnings, but paid no dividend because it was unable to record a profit for the fiscal year, among other reasons.
  7. FY2016First statedAnnual report

    「The Company recognizes the return of profits to shareholders as one of management's key priorities. Its basic policy is to maintain a strong management base, secure stable earnings, improve return on equity and pay sustainable, stable dividends. It also intends to use retained earnings to fund various investments that will further strengthen earning power and enhance corporate value.」

    The basic policy is to balance dividends with retained earnings and use retained earnings for investment in R&D and other areas.
Moved together

"Research Reagents and Contract Services Based on Antibody-Generation Technology" moved the same way as this thread, in the same document, in 6 of its 12 moves.

666554★123456
  1. ★This thread
  2. 1Research Reagents and Contract Services Based on Antibody-Generation Technology6×
  3. 2Expansion of Overseas Sales Activities6×
  4. 3Securing Earnings and Focusing Management Resources6×
  5. 4Improving Profitability Through a Change in the Sales Policy for the Diagnostics and Reagents Business5×
  6. 5Narrowing Operating Losses and Continued Losses5×
  7. 6Risk of losses and deterioration in operating cash flow associated with strengthening basic research4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet. It last moved in the Earnings of 2026-08-07: "Restated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Consistent, Stable Dividends and Reinvestment in Research and Development | Immuno-Biological Laboratories Co.,Ltd. (4570) | Komori